ERBB2 and breast carcinoma: Dorsomorphin, on the one hand, was more than four times more potent against BL-CL breast cancers (average EC50 = 9.33 μM) as compared with luminal/HER2+ breast cancer (average EC50 = 37.87 μM), which was a significant difference (p = 0.011, Figure 4A).